Abstract
A surge in cases of mucormycosis is occurring during India's catastrophic “second wave” of the COVID- 19 pandemic. Multiple actions are urgently needed to prevent and treat this life-threatening disease.
MeSH terms
-
Anti-Bacterial Agents / therapeutic use
-
COVID-19 / epidemiology*
-
COVID-19 / prevention & control
-
COVID-19 Drug Treatment
-
Comorbidity
-
Dexamethasone / therapeutic use
-
Diabetes Complications / immunology
-
Glucocorticoids / therapeutic use
-
Humans
-
Immunocompromised Host
-
India / epidemiology
-
Mucormycosis / drug therapy
-
Mucormycosis / epidemiology*
-
Mucormycosis / prevention & control
-
Prescription Drug Overuse
-
Risk Factors
-
SARS-CoV-2
-
Syndemic*
Substances
-
Anti-Bacterial Agents
-
Glucocorticoids
-
Dexamethasone